Premium
High expression of B lymphocyte stimulator in lesional keratinocytes of patients with cutaneous lupus erythematosus
Author(s) -
Wenzel Joerg,
Landmann Aysche,
Vorwerk Gero,
Kuhn Annegret
Publication year - 2018
Publication title -
experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.108
H-Index - 96
eISSN - 1600-0625
pISSN - 0906-6705
DOI - 10.1111/exd.13419
Subject(s) - b cell activating factor , belimumab , medicine , immunology , lupus erythematosus , monoclonal antibody , monoclonal , lymphocyte , receptor , systemic lupus erythematosus , pathology , antibody , disease , b cell
Belimumab, an anti‐B lymphocyte stimulator ( BL yS) monoclonal antibody, is approved for systemic lupus erythematosus; however, it is unclear if it can be used to treat specific skin lesions in this disease. In this analysis, we investigated the expression of BL yS and its receptors in skin lesions of different subtypes of cutaneous lupus erythematosus ( CLE ) using immunohistochemistry and gene expression analyses. Compared to healthy controls, the expression of BL yS was significantly higher in skin lesions of all included CLE subtypes. Similar results were seen for the BL yS receptors BAFF ‐R and BCMA . Moreover, CLE ‐typical pro‐inflammatory mediators (immunostimulatory DNA s) significantly enhanced the BL yS expression of keratinocytes in vitro. This study suggests a potential role for BL yS as therapeutic target in the treatment of CLE skin lesions.